Dermata Therapeutics, Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Consensus

—

Average target

$6.00

Implied upside

—

Analysts

—

Why Is DRMA Down Today?

Dermata Therapeutics shares fell 7.86% today despite announcing positive clinical progress on its second commercial product, Tome acne treatment. The disconnect between the clinical milestone and stock weakness suggests investors may be pricing in concerns about execution timelines, cash runway, or broader market conditions affecting biotech stocks.

Bottom line: Dermata's clinical progress on Tome is substantive, but today's 7.86% decline highlights investor caution regarding execution risks and the extended timeline to commercialization. Investors should monitor upcoming trial data and enrollment metrics closely, as successful milestones could provide compelling entry points, though near-term volatility should be expected in this early-stage biotech space.